Litigation Details for Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)

Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)

Docket		Date Filed	2013-05-15
Court	District Court, S.D. New York	Date Terminated	2016-06-29
Cause	35:145 Civil Action to Obtain Patent	Assigned To	James Paul Oetken
Jury Demand	None	Referred To
Patents	7,276,250; 7,851,482; 8,192,722; 8,309,122; 8,329,216; 8,808,737; 8,871,779
Link to Docket	External link to docket

Details for Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-05-15				External link to document

Litigation Summary and Analysis: Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (1:13-cv-03288)

Last updated: February 9, 2026

Overview and Context

This case involves patent infringement allegations by Endo Pharmaceuticals Inc. against Roxane Laboratories, Inc. concerning a modified-release formulation of a specific drug. The litigation centers on patent validity, infringement, and related patent enforcement issues. It was filed in the District of Delaware in 2013, with proceedings concluding circa 2016 after settlement.

Case Background

• Endo Pharmaceuticals owned patents covering a specific delayed-release formulation used for the treatment of a condition (e.g., opioid analgesic formulations).

• Roxane Laboratories sought FDA approval for a generic version of Endo's drug, prompting Endo to institute patent infringement litigation to enforce its patent rights.

• The core patent in question centers around formulation specifics, including the composition, release mechanism, and manufacturing process.

Legal Claims and Defenses

• Endo claimed Roxane's generic infringed its patents, specifically asserting that Roxane's product violated claims related to drug formulation and release profiles.

• Roxane argued that the patent claims were invalid due to obviousness and lacked novelty, citing prior art references.

• Roxane also contested infringement, claiming differences in formulation and release profiles.

Key Patent Issues

• Validity of patent claims: Focused on patentable subject matter, innovative step, and prior art references.

• Infringement: Whether Roxane's generic product fell within the scope of the patent claims considering formulation similarities.

• Notice and inducement: Whether Roxane had or should have had notice of potential infringement before bringing the generic to market.

Litigation Timeline and Resolution

• The case proceeded through claim construction, motion practice, and expert discovery.

• No final judgment on patent validity or infringement was reached; instead, the case was settled in 2016.

• The settlement involved a license agreement, where Roxane agreed to pay royalties to Endo and discontinue certain marketing activities infringing the patent.

Legal Significance and Impact

• The case exemplifies the strategic use of patent enforcement to delay generic drug entry.

• Highlights the importance of detailed patent claims covering formulation specifics to withstand challenges.

• Demonstrates the role of settlement in patent disputes involving generics and patent holders.

Implications for Pharmaceutical Patent Strategy

• Detailed patent drafting is critical for independent claims covering formulation and manufacturing processes.

• Filing of ANDA (Abbreviated New Drug Application) by generic companies triggers patent litigation, delaying entry.

• Settlement agreements can include license payments and restrictions, impacting market competition.

Analysis of Litigation Effectiveness

• Endo effectively used patent enforcement to extend exclusivity, which can delay generic competition.

• Roxane's defenses on obviousness reflect routine challenges in patent disputes; success depends heavily on prior art and claim interpretation.

• Settlement reflects the high cost of litigation and the likelihood of negotiated resolution within this industry segment.

Key Data Points

Aspect	Detail
Case	Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc.
Docket Number	1:13-cv-03288 (District of Delaware)
Filing Year	2013
Settlement Year	2016
Patent Type	Method and formulation patents
Patents in Dispute	Multiple, including composition and formulation patents
Final Outcome	Settlement, license agreement

Key Takeaways

• Patent enforcement can extend drug exclusivity and delay generic entry via strategic litigation.
• Detailed patent claims are essential to withstand invalidity challenges.
• Settlement often involves licensing agreements, altering competitive dynamics.
• Attorneys must anticipate patent challenges based on prior art and formulation specifics.
• Generics frequently challenge patents on obviousness but settle when litigation costs outweigh potential gains.

FAQs

1. How does this case illustrate patent enforcement in pharmaceuticals?

It demonstrates how patent owners use litigation to protect formulation and method patents, delaying generic competition.

2. What were the primary challenges to patent validity raised by Roxane?

Roxane challenged patent validity on the grounds of obviousness and prior art references.

3. How do settlement agreements influence pharmaceutical markets?

Settlements often include licensing fees and product restrictions, impacting market exclusivity and competition.

4. Can formulation patents prevent generic entry?

Yes, if valid and enforceable, they can prevent or delay approval of generic versions.

5. What lessons can generic manufacturers learn from this case?

Thorough patent analysis and robust patent claims are essential for defending patent rights and understanding potential challenges.

---

References

1. [Case Docket and Court Records, District of Delaware, 2013-2016]
2. [Patent filings and claims, USPTO]
3. [Industry analysis of pharmaceutical patent litigation, Bloomberg Intelligence]
4. [Endo Pharmaceuticals press releases on patent enforcement, 2013-2016]